Navigation Links
EntreMed Receives NASDAQ Listing Rule 5550(b)(2) Determination Letter
Date:8/19/2010

that its securities will be subject to delisting from the NASDAQ Capital Market. At that time, the Company will be permitted to appeal NASDAQ's determination to a Listing Qualifications Panel.

The Company intends to actively monitor its MVLS and alternative continued listing requirements to regain compliance with NASDAQ listing standards. The Company may seek to raise additional capital in conjunction with clinical developments over the course of the remaining year to increase stockholders' equity.

About EntreMedEntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including  the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the N
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
(Date:1/14/2014)... -- Acumed,s new SLIC Screw System - a jointed ... place and insert the screw accurately - offers surgeons ... repair or reconstruction as it holds the bones reduced ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw is ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... (Nasdaq: ERES ), a global provider of ... device industries, today announced that Michael McKelvey will be ... Officer and a director of ERT.  The Company,s Board ...  Dr. McKelvey will continue in his current position until ...
... Sept. 10 Covance Inc. (NYSE: CVD ) ... Global Healthcare Conference on Tuesday, September 14, 2010 at 2:10 ... presentation at www.covance.com .  In order to register and ... Covance, with headquarters in Princeton, New Jersey, is ...
Cached Medicine Technology:ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer 2ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer 3
(Date:4/17/2014)... the most popular vaccine brands for children may not ... overlooking some cost factors when choosing vaccines, driving the ... according to a new study by University of Illinois ... be driven by numerous factors," says Sheldon H. Jacobson, ... computer science and of mathematics at the U. of ...
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
(Date:4/17/2014)... MD, was recently invited to submit a review ... Microbiology , one of the world,s foremost scientific ... specialist, and chair of the Department of Pediatrics ... analyzed the epidemiology and microbiology of co-infections during ... as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... , , ORLANDO, Fla., ... new report today at its annual convention in Toronto acknowledging ... comes to dealing with conflicts between religious beliefs and same-sex ... conflict with their sexuality and faith, says this report acknowledges ...
... ... , ... Atlanta, GA (Vocus) August 5, 2009 -- CareFirst BlueCross BlueShield (CareFirst) today announced that ... in National Account Service Company LLC (NASCO), joining the Blue Cross and Blue Shield ...
... , , BOSTON, Aug. 5 ... management solutions, today reported unaudited financial results for the second quarter ended June ... ) , , Q2 Financial Highlights ... second quarter of 2009 was $23.5 million, compared to $13.6 million for the ...
... , , HARRISBURG, Pa., Aug. ... of Massage Therapy began drafting preliminary regulations that will protect ... Commonwealth Pedro A. Cortes. , , "By ... and training, we can provide the best and most up-to-date ...
... , , ST. PAUL, Minn., Aug. ... Extreme Makeover: Home Edition (EMHE) premieres its seventh season ... be among a select group as a Designated Charity for an ... Duluth/Superior area. The EMHE episode, air date to be announced at ...
... simply a marker for obesity is unclear , , WEDNESDAY, ... activates sex hormones throughout the body may also predict those ... study finds. , The protein, called sex hormone-binding globulin (SHBG), ... Researchers suspect it also plays a role in the development ...
Cached Medicine News:Health News:APA Releases Report on Sexuality Debate 2Health News:APA Releases Report on Sexuality Debate 3Health News:CareFirst Joins Partnership of Blues Plans as Owner of NASCO 2Health News:CareFirst Joins Partnership of Blues Plans as Owner of NASCO 3Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 2Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 3Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 4Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 5Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 6Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 7Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 8Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 9Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 10Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 11Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 12Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 13Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 14Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 15Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 16Health News:AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2009 17Health News:State Regulation of Massage Therapy Will Improve Public Health, Safety 2Health News:State Regulation of Massage Therapy Will Improve Public Health, Safety 3Health News:Memorial Blood Centers Joins Extreme Makeover: Home Edition As Designated Charity 2Health News:Memorial Blood Centers Joins Extreme Makeover: Home Edition As Designated Charity 3Health News:Sex Hormone Protein May Predict Type 2 Diabetes 2Health News:Sex Hormone Protein May Predict Type 2 Diabetes 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: